Journal Article
. 2017 Oct;4(1).
doi: 10.1001/jamaoncol.2017.3470.

Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Michaela Tsai 1 Shelly Lo 2 William Audeh 3 Rubina Qamar 4 Raye Budway 5 Ellis Levine 6 Pat Whitworth 7 Blanche Mavromatis 8 Robin Zon 9 Dwight Oldham 10 Sarah Untch 3 Tina Treece 3 Lisa Blumencranz 3 Hatem Soliman 11 
Affiliations
  • PMID: 29075751
  •     24 References
  •     14 citations

Abstract

Importance: Among patients who undergo the 21-gene assay (21-GA), 39% to 67% receive an intermediate risk result and may receive ambiguous treatment guidance. The 70-gene signature assay (70-GS) may be associated with physicians' treatment decisions in this population with early breast cancer.

Objective: To determine whether 70-GS findings are associated with physicians' decisions about adjuvant treatment and confidence in their recommendations and to evaluate the dichotomous (high- vs low-risk) and continuous distribution of 70-GS indices among this group of patients with intermediate risk.

Design, Setting, And Participants: The Prospective Study of MammaPrint in Breast Cancer Patients With an Intermediate Recurrence Score (PROMIS trial) was an impact study conducted from May 20, 2012, through December 31, 2015, that enrolled 840 patients with early-stage breast cancer and a 21-gene assay recurrence score of 18 to 30. Patients were treated in 58 US institutions.

Interventions: The 70-GS result was given to physicians before adjuvant treatment.

Main Outcomes And Measures: Change in physician treatment decision before vs after receiving the 70-GS result. With a treatment change of greater than 20%, the odds ratio (OR) was applied.

Results: Among the 840 patients who underwent 70-GS classification (mean age, 59 years; range, 27-93 years), 374 (44.5%) had a low-risk and 466 (55.5%) had a high-risk result. The distribution of 70-GS indices did not correlate with recurrence score within the 21-GA intermediate range, with 70-GS low- and high-risk patients observed at every recurrence score. A significant change in adjuvant treatment was associated with receiving the 70-GS classifications with an OR of 0.64 (95% CI, 0.50-0.82; McNemar test, P < .001) for all patients. Among the low-risk patients, 108 of 374 (28.9%) had chemotherapy removed from their treatment recommendation; among the high-risk patients, 171 of 466 (36.7%) had chemotherapy added. Results of the 70-GS were associated with the physician's adjuvant treatment recommendation; 409 high-risk patients (87.8%) were recommended to receive adjuvant chemotherapy, and 339 low-risk patients (90.6%) were recommended no chemotherapy. Physicians reported having greater confidence in their treatment recommendation in 660 cases (78.6%) based on 70-GS results.

Conclusions And Relevance: The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6%). Chemotherapy was added or withheld by the treating physician based on the results of the 70-GS test. Physicians reported more confidence with their treatment recommendation after receiving 70-GS results.

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.
Scott D Ramsey, William E Barlow, +6 authors, Gabriel N Hortobagyi.
Contemp Clin Trials, 2012 Sep 25; 34(1). PMID: 23000081    Free PMC article.
Review.
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
Michele M Gage, Martin Rosman, +6 authors, Lorraine Tafra.
Clin Breast Cancer, 2015 Jun 15; 15(6). PMID: 26072275    Free PMC article.
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Valesca P Retèl, Manuela A Joore, +3 authors, Wim H van Harten.
Eur J Cancer, 2010 Apr 03; 46(8). PMID: 20359886
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Laura J Esserman, Christina Yau, +9 authors, Linda S Lindström.
JAMA Oncol, 2017 Jul 01; 3(11). PMID: 28662222    Free PMC article.
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
Gene expression profiling in breast cancer.
Belisario A Arango, Celine L Rivera, Stefan Glück.
Am J Transl Res, 2013 Apr 11; 5(2). PMID: 23573359    Free PMC article.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.
Valesca P Retèl, Manuela A Joore, Wim H van Harten.
Breast Cancer Res Treat, 2011 Sep 29; 131(2). PMID: 21947677
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
L F Hutchins, J M Unger, +2 authors, K S Albain.
N Engl J Med, 1999 Dec 30; 341(27). PMID: 10615079
Highly Cited.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Laura J van 't Veer, Christina Yau, +6 authors, Linda Sofie Lindström.
Breast Cancer Res Treat, 2017 Aug 05; 166(2). PMID: 28776283    Free PMC article.
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Hyun-Seok Kim, Christopher B Umbricht, +22 authors, Leslie Cope.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998227    Free PMC article.
Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
V P Retèl, M A Joore, +5 authors, W H van Harten.
Eur J Cancer, 2013 Sep 03; 49(18). PMID: 23992641
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
M Elizabeth H Hammond, Daniel F Hayes, +31 authors, College of American Pathologists.
Arch Pathol Lab Med, 2010 Jul 01; 134(7). PMID: 20586616
Highly Cited. Systematic Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
J Clin Oncol, 2013 Oct 09; 31(31). PMID: 24101045
Highly Cited.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.
The PROMISe to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"?
Fatima Cardoso, Giuseppe Curigliano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845111    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?
Kathryn A Phillips, Deborah A Marshall, Allison W Kurian.
Per Med, 2019 Sep 26; 16(5). PMID: 31552799    Free PMC article.
Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma.
Yuanlei Chen, Shangjun Jiang, +7 authors, Gonghui Li.
J Cell Mol Med, 2019 Nov 30; 24(2). PMID: 31782902    Free PMC article.
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Hatem Soliman, Varsha Shah, +11 authors, William Audeh.
BMC Cancer, 2020 Feb 02; 20(1). PMID: 32005181    Free PMC article.
Open Access Information Added.
JAMA Oncol, 2017 Nov 24; 4(1). PMID: 29167873    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.
Whole transcriptome signature for prognostic prediction (WTSPP): application of whole transcriptome signature for prognostic prediction in cancer.
Evelien Schaafsma, Yanding Zhao, +4 authors, Chao Cheng.
Lab Invest, 2020 Mar 08; 100(10). PMID: 32144347    Free PMC article.
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.
Yuichiro Miyoshi, Tadahiko Shien, +14 authors, Hiroko Yamashita.
Oncol Lett, 2019 Jan 25; 17(2). PMID: 30675282    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
R Wuerstlein, R Kates, +14 authors, WSG-PRIMe investigators in Germany, Austria, Switzerland.
Breast Cancer Res Treat, 2019 Feb 24; 175(2). PMID: 30796651    Free PMC article.